Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BiomX Inc. COmmon Stock (NY:PHGE)

0.3895 -0.0185 (-4.53%)
Official Closing Price Updated: 4:10 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BiomX Inc. COmmon Stock

Market Alert: BiomX Trading Surges Following Phase 2b Trial Initiation in Cystic Fibrosis Program
Via AB Newswire
This $13M Biotech Has $40M in Pentagon Funding – Here’s Why BiomX Could Be Biotech’s Best-Kept Secret
This $13M Biotech Has $40M in Pentagon Funding – Here’s Why BiomX Could Be Biotech’s Best-Kept Secret 
Via News Direct
BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says
BiomX's breakthrough phage therapy delivers positive results in diseases that stumped Big Pharma for decades (NYSE: PHGE)* 
Via News Direct
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
Via AB Newswire
BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference
From BiomX Inc.
Via Business Wire
BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update
From BiomX Inc.
Via Business Wire
BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022
From BiomX Inc.
Via Business Wire
BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease
From BiomX
Via Business Wire
BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange
From BiomX Inc.
Via Business Wire
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
From BiomX Inc.
Via Business Wire
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
From BiomX Inc.
Via Business Wire
BiomX Announces Corporate Restructuring
From BiomX Inc.
Via Business Wire
BiomX Announces Publication in the Journal, Bioinformatics
From BiomX Inc.
Via Business Wire
BiomX Reports First Quarter 2022 Financial Results and Provides Business Update
From BiomX Inc.
Via Business Wire
BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients
From BiomX Inc.
Via Business Wire
BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022
From BiomX Inc.
Via Business Wire
BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
From BiomX Inc.
Via Business Wire
BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022
From BiomX Inc.
Via Business Wire
BiomX Presenting at Three Upcoming Investor Conferences
From BiomX Inc.
Via Business Wire
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation
From BiomX Inc.
Via Business Wire
BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages
From BiomX Inc.
Via Business Wire
BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference
From BiomX Inc.
Via Business Wire
BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates
From BiomX Inc.
Via Business Wire
BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021
From BiomX Inc.
Via Business Wire
BiomX to Present at Upcoming April Investor Events
From BiomX Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.